Cybin, Inc. (CYBN)

NYSEAMERICAN: CYBN · IEX Real-Time Price · USD
1.05 0.00 (0.00%)
Jan 14, 2022 4:00 PM EST - Market closed
Market Cap170.49M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out162.38M
EPS (ttm)-0.31
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume480,714
Open1.05
Previous Closen/a
Day's Range1.02 - 1.06
52-Week Range0.95 - 3.38
Betan/a
Analystsn/a
Price Targetn/a
Earnings DateNov 15, 2021

About CYBN

Cybin Inc., a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U.S., and Natures Journey. The Serenity Life and Cybin U.S. segment engages in the research and development of psychedelic pharmaceutical products. The Natures Journey segment focuses on non-psychedelic medicinal mushroom nutraceutical products. It develops CYB001, a drug candidate that is in phase IIa/b for major depressive disorder; CYB0...

IndustryBiotechnology
Founded2019
Employees38
Stock ExchangeNYSEAMERICAN
Ticker SymbolCYBN
Full Company Profile

Financial Performance

Financial numbers in millions CADFinancial Statements

News

Psychedelics Biotech Companies Mark New Milestones In Drug Development Pipelines: Field Trip, Cybin and Wesana

On Tuesday, three public companies in the psychedelics/biotech space announced significant milestones in their drug development pipelines. Field Trip Receives Notice Of Patent Allowance For Proprietary ...

Other symbols:FTRP
4 days ago - Benzinga

Why Cybin Shares Are Rising

Cybin Inc (NASDAQ: CYBN) shares are trading higher after the company announced an Institutional Review Board granted approval for a Cybin-sponsored feasibility study using Kernel Flow technology to meas...

4 days ago - Benzinga

Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Meas...

TORONTO--(BUSINESS WIRE)--Institutional Review Board Approves Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain

4 days ago - Business Wire

Cybin Announces Additional Adelia Milestone Achievement

TORONTO--(BUSINESS WIRE)--Cybin Announces Additional Adelia Milestone Achievement

1 week ago - Business Wire

Cybin Provides 2021 Year End Summary

TORONTO--(BUSINESS WIRE)--Cybin Provides 2021 Year End Summary

3 weeks ago - Business Wire

Cybin to Participate in the 11th Annual LifeSci Partners Corporate Access Event and H.C. Wainwright Bioconnect Confer...

TORONTO--(BUSINESS WIRE)--Cybin to Participate in the 11th Annual LifeSci Partners Corporate Access Event and H.C. Wainwright Bioconnect Conference

3 weeks ago - Business Wire

Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine...

TORONTO--(BUSINESS WIRE)--Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004

1 month ago - Business Wire

Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™” is pleased to announce...

1 month ago - Business Wire

Cybin to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference on December 8, 2021

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM” is pleased to announc...

1 month ago - Business Wire

Cybin To Test Psychedelic-Assisted Psychotherapy For COVID-Related Distress

The FDA authorized an investigator-initiated Phase 2 trial evaluating Cybin Inc's (NYSE: CYBN) psychedelic-assisted psychotherapy with psilocybin for frontline clinicians experiencing COVID-related dist...

1 month ago - Benzinga

Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase 2 Clinica...

TORONTO--(BUSINESS WIRE)--Cybin Announces FDA Investigational New Drug Approval for Phase 2 Clinical Trial for Frontline Clinicians Experiencing COVID-Related Distress

1 month ago - Business Wire

Cybin to Participate in the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021

TORONTO--(BUSINESS WIRE)--Cybin to Participate in the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021

1 month ago - Business Wire

Cybin Announces Additional Adelia Milestone Achievements

TORONTO--(BUSINESS WIRE)--Cybin Announces Additional Adelia Milestone Achievements

1 month ago - Business Wire

NY's Lenox Hill Hospital With Cybin-Awarded Grant Will Provide Psychedelic Therapy To City's Underserved

Psychedelic therapy company, Cybin Inc. (NEO: CYBN) (NYSE:CYBN), recently announced it was awarded a grant for the first psychedelic treatment clinic at New York City's Lenox Hill Hospital with which it...

1 month ago - Benzinga

Cybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved Communities

TORONTO--(BUSINESS WIRE)--Cybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved Communities

1 month ago - Business Wire

Cybin Reports Q2 Financial Results And Latest Business Highlights

Toronto-based, Cybin Inc. (NEO: CYBN) (NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics,” reported its unaudited financial results on Monday for the second q...

2 months ago - Benzinga

Cybin Inc. Reports its Second Quarter Financial Results and Recent Business Highlights

TORONTO--(BUSINESS WIRE)--Cybin Inc. Reports its Second Quarter Financial Results and Recent Business Highlights

2 months ago - Business Wire

Can The Psychedelics Boom Go Bust? A Conversation With Cybin Chief Clinical Officer Dr. Alex Belser

This article was originally published on Psychedelic Spotlight and appears here with permission. "Something that people used to speak about only in whispers is now standard policy," says the psychedelic...

2 months ago - Benzinga

Cybin to Present at the Jefferies London Healthcare Conference

TORONTO--(BUSINESS WIRE)--Cybin to Present at the Jefferies London Healthcare Conference

2 months ago - Business Wire

Cybin to Announce Second Quarter FY2021 Financial Results and Business Update on November 15, 2021

TORONTO--(BUSINESS WIRE)--Cybin to Announce Second Quarter FY2021 Financial Results and Business Update on November 15, 2021

2 months ago - Business Wire

Cybin Announces Positive Data Showing Effectiveness of Psilocybin To Treat Depression

Cybin Inc (NYSE: CYBN), a Toronto-based biotechnology company focused on utilizing psychedelic drugs as an alternative to traditional psychiatric drugs, announced positive pre-clinical data, indicating ...

2 months ago - Benzinga

Why Cybin Stock Is Down on Monday

Positive pre-clinical data for CYB003 isn't nearly as exciting as investors hoped it would be.

2 months ago - The Motley Fool

Cybin Announces Positive CYB003 Data Demonstrating Significant Advantages Over Oral Psilocybin for Treatment of Menta...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today announced posi...

2 months ago - Business Wire

Cybin Gets DEA License To Work With Scheduled Psychedelic Molecules

Cybin Inc. (NYSE:CYBN) a company developing novel psychedelic compounds for therapeutic use, has received a Schedule I manufacturing license from the U.S. Drug Enforcement Agency (DEA). The DEA license ...

2 months ago - Benzinga

Cybin Granted DEA Schedule I Manufacturing License

TORONTO--(BUSINESS WIRE)--Cybin Granted DEA Schedule I Manufacturing License

2 months ago - Business Wire